NOVAVAX
Bookmark
ShareCopied to clipboardNOVAVAX is a company. It is a public company in Gaithersburg, the United States. It was founded in 1987 and its current CEO is Stanley Charles Erck. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Gaithersburg
- state: MD
- country: United States
- employees: 1,541 people
- revenues: 1.4B $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1987
- CEO: Stanley Charles Erck
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about NOVAVAX:
Dataset of stocks from NOVAVAX:
NOVAVAX is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Gaithersburg and 3,456,835 companies in our database.
Talking Points
- Creating vaccines and driving value through partnerships and R&D | Novavax
- Novavax is a global biotechnology company with a proven vaccine technology, focused on developing our R&D assets and establishing partnerships to help protect health.
- Producing next-generation vaccines with global access for more people. See what’s developing at https://t.co/apuZo0qpnM.
- Producing next-generation vaccines with global access for more people. ... Jobs at NOVAVAX INC Manager, Biostatistics ... CureVac Biotechnology Tübingen, Baden-Württemberg Johnson & Johnson Hospital & Health Care ...
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Committed to creating vaccines to help protect health | Novavax
- We are a biotechnology company committed to addressing serious infectious diseases globally through the discovery and development of innovative vaccines.
- New Era of Revolutionary Vaccines EUA in the USA | Novavax